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Introduction
The long-term goal of this project is to understand how Paget's Disease of Bone (PDB) begins and the role of measles virus in that initiation. PDB can be inherited in families and several genes have been linked to PDB including Sequestosome 1 (SQSTM1), which has been linked to 40% of familial PDB (1) . Measles virus infection has also been linked to PDB in a substantial fraction of cases (2, 3) . One of the key questions in PDB is the nature of the "trigger" for initiation of the disease (4) . As an illustrative example, individuals in a family with familial PDB inherit a germline mutation in the SQSTM1 gene that predisposes those individuals to PDB. A predisposed individual contracts measles at age 8, which is the only other known factor for PDB. However, the disease does not reveal itself until that individual reaches age 50. What has occurred in the intervening time period that was not present at age 8 is the basis for this proposal. Our model involves the genes of the measles virus genome. The measles virus genome contains a number of genes. Two of these genes, the MVNP protein and the MVV gene appear to act in opposing fashion to control gene expression in an infected cell (2, (5) (6) (7) (8) (9) . The MVV gene suppresses gene expression as part of the virus' ability to evade immunological surveillance and promote persistent infection (5, 6) . In contrast, the MVNP gene appears to activate gene expression to promote acute infection (10) (11) (12) . Our hypothesis is that when the measles virus infects a bone cell, the MVV gene creates a latent infection state by suppressing gene expression in the cell. Then, over the years, a chance genetic event in a single bone cell containing the measles virus results in the loss of the MVV gene. At this time, the MVNP gene is unmasked and cooperates with the mutated SQSTM1 to initiate the exaggerated pattern of bone cell growth characteristic of PDB. In the first aim, we proposed to introduce both the MVV and MVNP genes into bone cells in culture and then use siRNA technology to turn off the MVV gene and observe the change in the growing bone cells to see if it mimics PDB. Our Statement of Work proposed that we would clone the MVV gene from the measles' genome and co-transfect it together with the MVNP gene into pre-osteoclasts. We would then selectively inhibit MVV and MVNP by siRNA and examine the phenotype of the cells.
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In the second aim, we proposed to examine affected bone tissue from patients with PDB to see if the affected bone has evidence of mutation of the MVV gene while maintaining the MVNP gene. Our Statement of Work proposed that we would use laser capture microdissection (LCM) to capture pagetic cells and then analyze RNA from these cells for expression of MVV and MVNP and mutation in MVV.
What was accomplished under these goals?
As noted in our 2014 Annual Summary Report, almost immediately, we ran into problems with the MVV gene. As is shown in Figure 1 , the MVV gene and the MVP genes are encoded by a common sequence in the measles virus genome in which both use the ATG start site at nucleotide 1807 and from 1807 to 2498 show a common translated amino acid sequence. The two sequences diverge due to a non-templated insertion of a G nucleotide at nucleotide 2499 in the MVV sequence resulting in a frameshift and altered reading resulting in a unique amino acid sequence for MVP and MVV from that point on. Our attempts at cloning this sequence of the MVV gene from the measles' genome using a PCR-based strategy in which we assemble the MVV gene from the measles virus genomic RNA using overlapping primer sets were ultimately unsuccessful. As our major objectives for this last year of the grant, we proposed two alternative strategies for this aim: The first was to adopt a two-step procedure where a truncated MVP gene sequence (approximately nucleotides 1800 -3000) was amplified by PCR and cloned into a vector and then the non-templated MVV G nucleotide at 2499 would be inserted into the cloned MVP gene sequence by a second PCR reaction or restriction reaction. Our second alternative was to isolate the MVV RNA from cells infected with the intact Measles virus and then use that RNA as template to clone the MVV gene. Unfortunately, both of those strategies also ultimately failed. We were unable to clone the MVV gene from the measles genome.
With regard to our second objective, in which we proposed to examine the RNA from pagetic cells, we were able to capture cells by LCM, however, we were unable to distinguish amplification of the MVV gene from the MVP gene as the primer sets that we were able to develop for PCR amplification did not include the region containing the non-templated G nucleotide.
Therefore, as an attempt to salvage the ultimate goal of the project, which was to understand the effect of the measles' genome on the initiation of the pagetic phenotype, we altered the focus of the work towards a new approach, which was an in vitro analysis to compare cells in which both the SQSTM1 mutation and the measles' genome were already present with those of a normal human cell into which the SQSTM1 mutation was introduced without the accompanying measles' genome and to then examine the genomic signatures of the two cell lines by RNA-seq analysis to see what genes were differentially expressed in the two cells. We could then also expose these two cell lines to environmental triggers (LPS and Vitamin D3) and see what genes were differentially expressed in the cells carrying both the SQSTM1 mutation and the measles virus genome compared to those that carried the SQSTM1 mutation alone.
The experimental approach is outlined in Table 1 . For our normal human cell carrying the SQSTM1 mutation, we stably introduced the SQSTM1 P392L predisposing mutation into the human fetal osteoblast cell line hFOB1.19 (13) under the CMV promoter. We have found that the hFOB cell line approximates the genomic expression pattern of normal primary human osteoblasts without the difficulty of using primary human cell cultures. For our pagetic osteoblast, we used the PSV10 osteoblast cell line isolated from a patient with hereditary Paget's disease (14) that is positive for measles virus genome. We treated these two cell lines (and the hFOB cells without the SQSTM1 mutation as a control) with bacterial lipopolysaccharide (LPS) and Vitamin D to simulate the environmental trigger to initiates Paget's disease of bone. We then isolated RNA from the treated and untreated cells and subjected them to whole genome RNA-seq (15, 16) . The RNA-seq was performed by the Beth Israel-Deaconess Genomics, Proteomics, Bioinformatics, and Systems Biology Center and DF/HCC Cancer Proteomics Core (Towia Liberman, Director). The RNAs were analyzed for quality control by Agilent Bio-analyzer and then the sequencing libraries were prepared using Qiagen GeneRead Library Prep kits (GeneRead DNA Library I Core Kit, GeneRead DNA I Amp Kit and GeneRead Adapter I Set 1-plex). The samples were barcoded to allow multiplexing. The libraries were then sequenced using an Illumina HiSeq2500 Next Generation sequencing system and 20 million single-pair reads were performed for each sample. The sequencing data was then returned to us as FASTQ files. This happened on 15 September 2015. Using Bowtie2, a software package commonly used for sequence alignment and sequence analysis in bioinformatics (17) combined with TopHat, Cufflinks and CummeRbund software packages, we were able to generate a genetic signature from this comparison of genes that were turned on or turned off in the presence of the measles' genome or in the presence of the SQSTM1 mutation. This genomic signature is shown in Table 2 . We are presently validating the genomic signature qPCR and analyzing it for insights into altered genetic pathways. One example of the types of genetic interaction information that can be gleaned from this work is shown in Figure 2 . The genes that are upregulated in response to the measles virus genome were loaded into the GeneMania web interface (http://www.genemania.org) and analyzed for genetic interactions. The green lines represent known genetic interactions between these genes.
What opportunities for training and professional development has the project provided?
Nothing to report
How were the results disseminated to communities of interest?
Upon completion of our validation of the genomic signature, we intend to submit a BCAT1  BCL2A1  ARPP21  FBN2  CNR1  CDK18  CCL3  CSTA  CKB  CCL5  CXCL5  ERG  CD22  DCLK1  FBXO44  GRAP2  DGKD  GNG11  IFNL1  DLG1  IFNL2  PCSK6  EDIL3  IFNL3  SERPINB10  EFCAB4B  IGFBP6  SERPINB2  EFEMP1  IL11  SPINK1  FAM129B  IRAK2  TMEM100  FAM171A1  KLF4  FHL1  MAPK10  FOXF2  PAX8  MYO10  PTGS2  NLGN4Y  SALL1  PCDHB2  SAT1  PCDHB3  VGF  PCDHB5  ZBP1  PREX1  SATB1  SETD7  SH3BP4  SIPA1L2  SMG1  SUSD5  Table 2 . Preliminary genomic signature of effect of measles virus genome and mutant SQSTM1 on gene expression. manuscript on the results of out comparison. At that time, we will submit the RNA-seq data to the NCBI GEO database so that it will be available to the research community.
What do you plan to do next?
This is the final report -therefore there is nothing to report. We plan to complete the validation of the genomic signature and publish that signature as well as the complete dataset.
Impact
What was the impact on the development of the principal discipline(s) of the project?
At this stage, we are still completing the validation of the genomic signatures to allow us to write manuscripts about the data generated. Therefore nothing to report. Once the signature is validated and published, it should have a significant impact on the field of Paget's disease.
What was the impact on other disciplines?
What was the impact on technology transfer? Nothing to report
What was the impact on society beyond science and technology? Nothing to report
Changes/Problems
Changes in approach and reasons for change As noted above, we were unable to clone the MVV gene or detect its expression in the pagetic samples. We therefore changed the experimental plan to examine the effects of the measles' genome in the context of a mutant SQSTM1 gene allele in an in vitro approach in which cells from a familial Paget's disease patient that already had the measles genome and a mutant SQSTM1 allele present in the cell were compared to cells that had only a mutant SQSTM1 allele. The change in approach is described in the Accomplished Goals section above. The goal was to develop a genomic signature that would allow us to determine what genetic pathways are altered by the expression of the measles virus genome in these cells.
Actual or anticipated problems or delays and actions or plans to resolve them
Nothing to report 
Changes that had a significant impact on expenditures

Other Products
We have obtained a preliminary genomic signature for cells containing the measles virus genome and a mutant SQSTM1 allele as well as a genomic signature of cells with a mutant SQSTM1 allele. Once this is validated, it will be submitted for publication and the genomic sequencing data submitted to the NCBI GEO database. 
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